{"id":788175,"date":"2023-10-04T16:10:14","date_gmt":"2023-10-04T20:10:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/"},"modified":"2023-10-04T16:10:14","modified_gmt":"2023-10-04T20:10:14","slug":"omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/","title":{"rendered":"Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics"},"content":{"rendered":"
\n

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) — Omega Therapeutics, Inc. (Nasdaq: OMGA) (\u201cOmega\u201d), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines,\u00a0today announced that it will present new preclinical data supporting the potential of OTX-2101, a c-MYC (MYC)-targeting epigenomic controller being developed for the treatment of non-small cell lung cancer (NSCLC), at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place in Boston, Massachusetts, October 11 \u2013 15, 2023.<\/p>\n

\u201cWe are excited to present new preclinical data from our NSCLC program that build on our recent preliminary clinical results in hepatocellular carcinoma, which demonstrated for the first time our ability to modulate MYC expression pre-transcriptionally in humans using a programmable mRNA development candidate,\u201d said Mahesh Karande, President and Chief Executive Officer of Omega Therapeutics. \u201cThese new data highlight the broad applicability of our MYC-targeting strategy across solid tumors and its potential to synergize with clinically validated therapeutic options. We look forward to advancing our preclinical and clinical studies to address MYC-driven cancers.\u201d<\/p>\n

\n Details for the poster presentation are as follows:<\/strong>\n <\/p>\n

\n Title:<\/strong> Targeted epigenomic modulation of MYC enhances responses to immune checkpoint and EGFR inhibitors in preclinical models of NSCLC
Poster number:<\/strong> C104
Session Information:<\/strong> Poster Session C
Date and Time: <\/strong>October 14, 2023, from 12:30 p.m. to 4:00 p.m. EDT<\/p>\n

The poster will be made available on the Omega website at https:\/\/omegatherapeutics.com\/our-science\/#publications-research<\/a> at the same time as the presentation.<\/p>\n

\n
\n About Omega Therapeutics<\/u>
\n <\/strong>
\n
Omega Therapeutics is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines to treat or cure a broad range of diseases. By pre-transcriptionally modulating gene expression, Omega\u2019s approach enables controlled epigenomic modulation of nearly all human genes, including historically undruggable and difficult-to-treat targets, without altering native nucleic acid sequences. Founded in 2017 by Flagship Pioneering following breakthrough research by world-renowned experts in the field of epigenetics, Omega is led by a seasoned and accomplished leadership team with a track record of innovation and operational excellence. The Company is committed to revolutionizing genomic medicine and has a diverse pipeline of therapeutic candidates derived from its OMEGA platform spanning oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.<\/p>\n

For more information, visit\u00a0omegatherapeutics.com<\/a>, or follow us on\u00a0X<\/a>\u00a0(formerly Twitter)\u00a0and\u00a0LinkedIn<\/a>.<\/p>\n

\n
\n Forward-Looking Statements<\/u>
\n <\/strong>
\n
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the potential of the OMEGA platform to engineer programmable epigenomic mRNA therapeutics that successfully and pre-transcriptionally regulate gene expression by targeting insulated genomic domains; expectations surrounding the potential of our product candidates, including OTX 2101 and OTX-2002; expectations regarding our pipeline, including trial design, initiation of preclinical studies and advancement of multiple preclinical development programs in oncology, immunology, regenerative medicine, and select monogenic diseases; and upcoming events and presentations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the novel technology on which our product candidates are based makes it difficult to predict the time and cost of preclinical and clinical development and subsequently obtaining regulatory approval, if at all; the substantial development and regulatory risks associated with epigenomic controllers due to the novel and unprecedented nature of this new category of medicines; our limited operating history; the incurrence of significant losses and the fact that we expect to continue to incur significant additional losses for the foreseeable future; our need for substantial additional financing; our investments in research and development efforts that further enhance the OMEGA platform, and their impact on our results; uncertainty regarding preclinical development, especially for a new class of medicines such as epigenomic controllers; potential delays in and unforeseen costs arising from our clinical trials; the fact that our product candidates may be associated with serious adverse events, undesirable side effects or have other properties that could halt their regulatory development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences; the impact of increased demand for the manufacture of mRNA and LNP based vaccines to treat COVID-19 on our development plans; difficulties manufacturing the novel technology on which our OEC candidates are based; our ability to adapt to rapid and significant technological change; our reliance on third parties for the manufacture of materials; our ability to successfully acquire and establish our own manufacturing facilities and infrastructure; our reliance on a limited number of suppliers for lipid excipients used in our product candidates; our ability to advance our product candidates to clinical development; and our ability to obtain, maintain, enforce and adequately protect our intellectual property rights. These and other important factors discussed under the caption \u201cRisk Factors\u201d in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, and our other filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management\u2019s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.<\/p>\n


\n
\n \n <\/div>\n

\n
Contact\r\nInvestor contact:\r\nEva Stroynowski\r\n617.949.4370\r\nestroynowski@omegatx.com\r\n\r\nMedia contact:\r\nJason Braco\r\nLifeSci Communications\r\n646.751.4361\r\njbraco@lifescicomms.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"
CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) — Omega Therapeutics, Inc. (Nasdaq: OMGA) (\u201cOmega\u201d), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines,\u00a0today announced that it will present new preclinical data supporting the potential of OTX-2101, a c-MYC (MYC)-targeting epigenomic controller being developed for the treatment of non-small cell lung cancer (NSCLC), at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place in Boston, Massachusetts, October 11 \u2013 15, 2023. \u201cWe are excited to present new preclinical data from our NSCLC program that build on our recent preliminary clinical results in hepatocellular carcinoma, which demonstrated for the first time our ability to modulate MYC expression pre-transcriptionally in humans using … <\/p>\n
Continue reading “Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-788175","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nOmega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) — Omega Therapeutics, Inc. (Nasdaq: OMGA) (\u201cOmega\u201d), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines,\u00a0today announced that it will present new preclinical data supporting the potential of OTX-2101, a c-MYC (MYC)-targeting epigenomic controller being developed for the treatment of non-small cell lung cancer (NSCLC), at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place in Boston, Massachusetts, October 11 \u2013 15, 2023. \u201cWe are excited to present new preclinical data from our NSCLC program that build on our recent preliminary clinical results in hepatocellular carcinoma, which demonstrated for the first time our ability to modulate MYC expression pre-transcriptionally in humans using … Continue reading "Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-04T20:10:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MzgwOSM1ODU3MDEwIzIyMDY5Njk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics\",\"datePublished\":\"2023-10-04T20:10:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/\"},\"wordCount\":941,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0MzgwOSM1ODU3MDEwIzIyMDY5Njk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/\",\"name\":\"Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0MzgwOSM1ODU3MDEwIzIyMDY5Njk=\",\"datePublished\":\"2023-10-04T20:10:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0MzgwOSM1ODU3MDEwIzIyMDY5Njk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0MzgwOSM1ODU3MDEwIzIyMDY5Njk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) — Omega Therapeutics, Inc. (Nasdaq: OMGA) (\u201cOmega\u201d), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines,\u00a0today announced that it will present new preclinical data supporting the potential of OTX-2101, a c-MYC (MYC)-targeting epigenomic controller being developed for the treatment of non-small cell lung cancer (NSCLC), at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place in Boston, Massachusetts, October 11 \u2013 15, 2023. \u201cWe are excited to present new preclinical data from our NSCLC program that build on our recent preliminary clinical results in hepatocellular carcinoma, which demonstrated for the first time our ability to modulate MYC expression pre-transcriptionally in humans using … Continue reading \"Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/","og_site_name":"Market Newsdesk","article_published_time":"2023-10-04T20:10:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MzgwOSM1ODU3MDEwIzIyMDY5Njk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","datePublished":"2023-10-04T20:10:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/"},"wordCount":941,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MzgwOSM1ODU3MDEwIzIyMDY5Njk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/","name":"Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MzgwOSM1ODU3MDEwIzIyMDY5Njk=","datePublished":"2023-10-04T20:10:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MzgwOSM1ODU3MDEwIzIyMDY5Njk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MzgwOSM1ODU3MDEwIzIyMDY5Njk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/omega-therapeutics-to-present-new-preclinical-data-on-otx-2101-at-the-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/788175","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=788175"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/788175\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=788175"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=788175"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=788175"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}